Functional Polymorphism in the Interleukin-6 and Interleukin-10 Genes in Patients with Paranoid Schizophrenia —A Case-Control Study
- 378 Downloads
Schizophrenia is a multifactorial disease with changes in immunological system. Such changes are the result of cytokine-level disturbances connected with cytokine gene polymorphisms. However, research about cytokine gene polymorphisms in schizophrenia has been surprisingly limited and ambiguous. The aim of the study was to identify whether polymorphisms of interleukin (IL)-6 and IL-10 are risk factors for the development of paranoid schizophrenia in case-control study. IL-6 (−174G/C; rs 1800795) and IL-10 (−1082G/A; rs 1800896) promoter polymorphisms in patients with paranoid schizophrenia and healthy individuals were genotyped using polymerase chain reaction–restriction fragment length polymorphism method. Differences in IL-6 and IL-10 promoter haplotypes may play an important role in determining the transcription level for IL-6 and IL-10 genes in schizophrenic patients. The presence of allele C at position −174 of IL-6 promoter sequence may correlate with increasing risk of paranoid schizophrenia in the Polish population, but research on a broadened group of people is needed. The presence of allele G at position −1082 of IL-10 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population. The coexistence of genotype GG at position −1082 of IL-10 promoter sequence and genotype GC at position −174 of IL-6 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population.
KeywordsInterleukin-6 Interleukin-10 Paranoid schizophrenia Polymorphism
We would like to thank Dr. Krzysztof Kucia for qualifying patients for the research and for collecting blood samples.
- Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C (2006) Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 33:703–708PubMedGoogle Scholar
- Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE (2001) Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458–1463.CrossRefPubMedGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV® Axis I disorders (SCID-I), clinician version. American Psychiatric Press, WashingtonGoogle Scholar
- García-Miss MR, Pérez-Mutul J, López-Canul B, Solís-Rodríguez F, Puga-Machado L, Oxté-Cabrera A, Gurubel-Maldonado J, Arankowsky-Sandoval G (2009) Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psych Res doi: 10.1016/j.jpsychires.2009.10.011
- Hauser J, Dmitrzak-Węglarz M (2009) In search of schizophrenia genes. Neuropsych and Neuropsychol 4(1):1–9Google Scholar
- Leonard B (2005) Is there an immunologic basis for schizophrenia? Expert Rev Clin Immunol 1:103–112Google Scholar
- Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Lin A, Racagni G, Altamura CA (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10:119–24CrossRefPubMedGoogle Scholar
- Ozbey U, Tug E, Namli M (2009) Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J Biol Psychiatry 10(4 Pt 2):461–468Google Scholar
- Zdanov A (2006) Title of chapter. In: Interleukin-10, Marincola FM (ed) National Institutes of Health, Georgetown, TX: Landes Bioscience, pp 1–10Google Scholar